IndustryCompany release

BioHarvest Sciences posts Q3 net loss of $3.3M as revenue falls to $7.9M

Bioharvest Sciences Inc. (BHST) · Thu 12 Nov 2026

The Nasdaq-listed botanical synthesis company reports lower cash at $12.5M and a September 2026 dual listing on the Tel Aviv Stock Exchange.

BioHarvest Sciences, a Nasdaq-listed biotechnology company built around a botanical synthesis platform, has reported a net loss of $3.3M for the third quarter of 2026. Revenue for the quarter fell to $7.9M.

The figures come from unaudited financial statements for the three and nine months ended 30 September 2026, which were approved on 12 November 2026. Over the nine months, revenue totalled $25.2M and the net loss was $9.7M.

Cash and equivalents stood at $12.5M at the end of September, down from $23.0M at the end of 2025. The company also added a dual listing on the Tel Aviv Stock Exchange in September 2026.

The material available gives no breakdown by product or segment and no explanation for the quarterly revenue decline, so the drivers are not covered here.

What it means for your team

  • Partners and suppliers of BioHarvest may want to review the company's reduced cash position, which fell from $23.0M to $12.5M over nine months.
  • The dual Nasdaq and Tel Aviv listing may bring additional disclosure obligations for the company, though the source does not detail them.
  • The figures are unaudited, and the available information does not explain the revenue movement; teams needing more detail should consult the full filing.

Company's press release (SEC filing): Bioharvest Sciences Inc. ↗

Article written by VigiEye from the official source (Bioharvest Sciences Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →